BMCAnest hesiology:罗哌卡因联合右美托咪定用于臂丛神经阻滞的镇痛效果

2019-09-30 anesthGH 罂粟花

罗哌卡因联合右美托咪定与罗哌卡因单独应用于臂丛神经阻滞镇痛效果的比较,为上肢外伤手术提供更好的麻醉方式。

背景与目的

罗哌卡因联合右美托咪定与罗哌卡因单独应用于臂丛神经阻滞镇痛效果的比较,为上肢外伤手术提供更好的麻醉方式。

方  法

试验共收集了我院2013年2月至2015年7月在臂丛神经阻滞麻醉下进行上肢手术的114例患者,并随机接受罗哌卡因单独麻醉(对照组)或罗哌卡因联合右美托咪定麻醉(联合组)。对照组30s内推注完20mL0.375%罗哌卡因;联合组30s内推注完20mL

0.375% 罗哌卡因+100μg右美托咪定。比较两组间感觉和运动神经元的阻滞效果、视觉模拟评分(VAS)、心率(HR)、平均动脉压(MAP)、外周毛细血管氧饱和度(SPO2)及不良反应。

结  果

与对照组相比,联合组感觉和运动神经阻滞的起效时间明显缩短(感觉阻滞8.9 min vs. 12.4 min,P < 0.05 ;运动阻滞7.5 min vs. 12.8min,P < 0.05 ),阻滞持续时间显着延长(590.2 min vs. 532.1 min, P <0.05)。两组间术后即刻及4h的VAS评分显着差异;然而,联合组术后8h、12h、24h的VAS评分均显着低于对照组(8h:2.4 vs. 3.0,P < 0.05;12h: 2.2 vs. 4.2,P < 0.05;24h:2.1 vs. 5.4,P < 0.05)。麻醉前两组间的HR、MAP 及SPO2?统计学差异;但麻醉后与对照组相?,联合组MAP和HR显着下降,SPO2明显升高(MAP:78 vs. 84,P < 0.05; HR:72 vs. 79,P <0.05;SPO2:95.1 vs. 88.2, P < 0.05)。联合组不良反应发生率明显低于对照组(3.6 vs. 7.2, P < 0.05)。

结  论

罗哌卡因联合右美托咪定于臂丛神经阻滞在术中及术后的镇痛效果优于罗哌卡因单独使用。

原始出处:

Zhenqing L, Menglu J, Tongsheng X,et al.Analgesic effect ofRopivacaine combined with Dexmedetomidine on brachial plexus block[J]. BMCAnest hesiology,2018,18(1):107.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2051444, encodeId=511320514443b, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Oct 15 06:38:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974955, encodeId=1ed719e495502, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Apr 17 10:38:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355329, encodeId=b1b7135532976, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Oct 02 12:38:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512573, encodeId=0c8315125e3cf, content=<a href='/topic/show?id=c964e959555' target=_blank style='color:#2F92EE;'>#罗哌卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79595, encryptionId=c964e959555, topicName=罗哌卡因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e2a10479591, createdName=ms6832696159214430, createdTime=Wed Oct 02 12:38:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588389, encodeId=05231588389ca, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Wed Oct 02 12:38:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628810, encodeId=7cd11628810d2, content=<a href='/topic/show?id=a717859399a' target=_blank style='color:#2F92EE;'>#臂丛神经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85939, encryptionId=a717859399a, topicName=臂丛神经)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1e621200257, createdName=zexyw08, createdTime=Wed Oct 02 12:38:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046920, encodeId=7b12104692012, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Oct 01 00:38:00 CST 2019, time=2019-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373389, encodeId=48b43e33891e, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Sep 30 21:47:55 CST 2019, time=2019-09-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2051444, encodeId=511320514443b, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Oct 15 06:38:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974955, encodeId=1ed719e495502, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Apr 17 10:38:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355329, encodeId=b1b7135532976, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Oct 02 12:38:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512573, encodeId=0c8315125e3cf, content=<a href='/topic/show?id=c964e959555' target=_blank style='color:#2F92EE;'>#罗哌卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79595, encryptionId=c964e959555, topicName=罗哌卡因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e2a10479591, createdName=ms6832696159214430, createdTime=Wed Oct 02 12:38:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588389, encodeId=05231588389ca, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Wed Oct 02 12:38:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628810, encodeId=7cd11628810d2, content=<a href='/topic/show?id=a717859399a' target=_blank style='color:#2F92EE;'>#臂丛神经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85939, encryptionId=a717859399a, topicName=臂丛神经)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1e621200257, createdName=zexyw08, createdTime=Wed Oct 02 12:38:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046920, encodeId=7b12104692012, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Oct 01 00:38:00 CST 2019, time=2019-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373389, encodeId=48b43e33891e, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Sep 30 21:47:55 CST 2019, time=2019-09-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2051444, encodeId=511320514443b, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Oct 15 06:38:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974955, encodeId=1ed719e495502, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Apr 17 10:38:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355329, encodeId=b1b7135532976, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Oct 02 12:38:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512573, encodeId=0c8315125e3cf, content=<a href='/topic/show?id=c964e959555' target=_blank style='color:#2F92EE;'>#罗哌卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79595, encryptionId=c964e959555, topicName=罗哌卡因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e2a10479591, createdName=ms6832696159214430, createdTime=Wed Oct 02 12:38:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588389, encodeId=05231588389ca, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Wed Oct 02 12:38:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628810, encodeId=7cd11628810d2, content=<a href='/topic/show?id=a717859399a' target=_blank style='color:#2F92EE;'>#臂丛神经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85939, encryptionId=a717859399a, topicName=臂丛神经)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1e621200257, createdName=zexyw08, createdTime=Wed Oct 02 12:38:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046920, encodeId=7b12104692012, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Oct 01 00:38:00 CST 2019, time=2019-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373389, encodeId=48b43e33891e, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Sep 30 21:47:55 CST 2019, time=2019-09-30, status=1, ipAttribution=)]
    2019-10-02 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=2051444, encodeId=511320514443b, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Oct 15 06:38:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974955, encodeId=1ed719e495502, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Apr 17 10:38:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355329, encodeId=b1b7135532976, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Oct 02 12:38:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512573, encodeId=0c8315125e3cf, content=<a href='/topic/show?id=c964e959555' target=_blank style='color:#2F92EE;'>#罗哌卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79595, encryptionId=c964e959555, topicName=罗哌卡因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e2a10479591, createdName=ms6832696159214430, createdTime=Wed Oct 02 12:38:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588389, encodeId=05231588389ca, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Wed Oct 02 12:38:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628810, encodeId=7cd11628810d2, content=<a href='/topic/show?id=a717859399a' target=_blank style='color:#2F92EE;'>#臂丛神经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85939, encryptionId=a717859399a, topicName=臂丛神经)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1e621200257, createdName=zexyw08, createdTime=Wed Oct 02 12:38:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046920, encodeId=7b12104692012, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Oct 01 00:38:00 CST 2019, time=2019-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373389, encodeId=48b43e33891e, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Sep 30 21:47:55 CST 2019, time=2019-09-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2051444, encodeId=511320514443b, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Oct 15 06:38:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974955, encodeId=1ed719e495502, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Apr 17 10:38:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355329, encodeId=b1b7135532976, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Oct 02 12:38:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512573, encodeId=0c8315125e3cf, content=<a href='/topic/show?id=c964e959555' target=_blank style='color:#2F92EE;'>#罗哌卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79595, encryptionId=c964e959555, topicName=罗哌卡因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e2a10479591, createdName=ms6832696159214430, createdTime=Wed Oct 02 12:38:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588389, encodeId=05231588389ca, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Wed Oct 02 12:38:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628810, encodeId=7cd11628810d2, content=<a href='/topic/show?id=a717859399a' target=_blank style='color:#2F92EE;'>#臂丛神经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85939, encryptionId=a717859399a, topicName=臂丛神经)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1e621200257, createdName=zexyw08, createdTime=Wed Oct 02 12:38:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046920, encodeId=7b12104692012, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Oct 01 00:38:00 CST 2019, time=2019-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373389, encodeId=48b43e33891e, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Sep 30 21:47:55 CST 2019, time=2019-09-30, status=1, ipAttribution=)]
    2019-10-02 skhzy
  6. [GetPortalCommentsPageByObjectIdResponse(id=2051444, encodeId=511320514443b, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Oct 15 06:38:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974955, encodeId=1ed719e495502, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Apr 17 10:38:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355329, encodeId=b1b7135532976, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Oct 02 12:38:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512573, encodeId=0c8315125e3cf, content=<a href='/topic/show?id=c964e959555' target=_blank style='color:#2F92EE;'>#罗哌卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79595, encryptionId=c964e959555, topicName=罗哌卡因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e2a10479591, createdName=ms6832696159214430, createdTime=Wed Oct 02 12:38:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588389, encodeId=05231588389ca, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Wed Oct 02 12:38:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628810, encodeId=7cd11628810d2, content=<a href='/topic/show?id=a717859399a' target=_blank style='color:#2F92EE;'>#臂丛神经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85939, encryptionId=a717859399a, topicName=臂丛神经)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1e621200257, createdName=zexyw08, createdTime=Wed Oct 02 12:38:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046920, encodeId=7b12104692012, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Oct 01 00:38:00 CST 2019, time=2019-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373389, encodeId=48b43e33891e, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Sep 30 21:47:55 CST 2019, time=2019-09-30, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2051444, encodeId=511320514443b, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Oct 15 06:38:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974955, encodeId=1ed719e495502, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Apr 17 10:38:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355329, encodeId=b1b7135532976, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Oct 02 12:38:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512573, encodeId=0c8315125e3cf, content=<a href='/topic/show?id=c964e959555' target=_blank style='color:#2F92EE;'>#罗哌卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79595, encryptionId=c964e959555, topicName=罗哌卡因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e2a10479591, createdName=ms6832696159214430, createdTime=Wed Oct 02 12:38:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588389, encodeId=05231588389ca, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Wed Oct 02 12:38:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628810, encodeId=7cd11628810d2, content=<a href='/topic/show?id=a717859399a' target=_blank style='color:#2F92EE;'>#臂丛神经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85939, encryptionId=a717859399a, topicName=臂丛神经)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1e621200257, createdName=zexyw08, createdTime=Wed Oct 02 12:38:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046920, encodeId=7b12104692012, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Oct 01 00:38:00 CST 2019, time=2019-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373389, encodeId=48b43e33891e, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Sep 30 21:47:55 CST 2019, time=2019-09-30, status=1, ipAttribution=)]
    2019-10-01 CHANGE

    疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2051444, encodeId=511320514443b, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Oct 15 06:38:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974955, encodeId=1ed719e495502, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Apr 17 10:38:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355329, encodeId=b1b7135532976, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Oct 02 12:38:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512573, encodeId=0c8315125e3cf, content=<a href='/topic/show?id=c964e959555' target=_blank style='color:#2F92EE;'>#罗哌卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79595, encryptionId=c964e959555, topicName=罗哌卡因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e2a10479591, createdName=ms6832696159214430, createdTime=Wed Oct 02 12:38:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588389, encodeId=05231588389ca, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Wed Oct 02 12:38:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628810, encodeId=7cd11628810d2, content=<a href='/topic/show?id=a717859399a' target=_blank style='color:#2F92EE;'>#臂丛神经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85939, encryptionId=a717859399a, topicName=臂丛神经)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1e621200257, createdName=zexyw08, createdTime=Wed Oct 02 12:38:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046920, encodeId=7b12104692012, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Oct 01 00:38:00 CST 2019, time=2019-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373389, encodeId=48b43e33891e, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Sep 30 21:47:55 CST 2019, time=2019-09-30, status=1, ipAttribution=)]
    2019-09-30 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

相关资讯

Anesthesiology:胸段硬膜外麻醉中罗哌卡因与布比卡因分别对下尿路功能的影响:随机临床实验

使用罗哌卡因与布比卡因相比,在胸段硬膜外镇痛法中使用罗哌卡因可以显著降低排尿后残余,对逼尿肌功能损害更小。

Medicine :臂丛神经阻滞,左布比卡因和罗哌卡因的术后镇痛效果并无差异

在药物的基础上,一般认为左布比卡因较罗哌卡因可持续更长的时间。然而,大多数报告臂丛阻滞时这两种麻醉剂在镇痛效果上并未存在明显的差异。本研究旨在对比左布比卡因和罗哌卡因用于治疗超声引导下臂丛神经阻滞术后的镇痛效果。 研究共纳入62名接受骨科手术的患者,随机接受左布比卡因( L组、n = 31)或罗哌卡因(R组,n = 31  )。记录患者术后镇痛持续时间、运动阻滞偏移时间、术后镇痛药用量及术后

Anesth Analg:持续性罗哌卡因切口局部浸润与鞘内注射吗啡在剖宫产后镇痛效果中的比较:前瞻性、随机对照、双盲试验

剖宫产后,术后疼痛管理可以促进早期康复,有助于预防产后抑郁症和慢性疼痛。目前的前瞻性、随机对照、双盲研究评估了剖宫产分娩后鞘内镇痛和连续罗哌卡因伤口浸润的持续时间和作用。主要结局是镇痛持续时间,其定义为首次增加使用吗啡的时间。次要结局是术后吗啡的累积用量,不需使用吗啡的患者数量,不良反应的发生率和首次下床活动的时间。

Anesthesiology:胸段硬膜外镇痛对下尿路功能的影响:罗哌卡因与布比卡因的比较

布比卡因胸段硬膜外镇痛可导致临床相关的由于逼尿肌松弛而引起的尿液残留。本研究通过评估尿液残留量和最大流量速率,从而比较使用罗哌卡因与布比卡因对膀胱功能障碍的影响程度。我们的假设为罗哌卡因会导致较低水平的尿液残留,由于已证明罗哌卡因对运动神经阻滞的作用较小。

World Neurosurg:比较罗哌卡因止血明胶海绵和生理盐水对脊柱内固定手术患者术后疼痛的影响:一项随机临床试验

目前,对于脊柱手术患者术后疼痛的控制尚无确切方案。本研究旨在比较应用含罗哌卡因可吸收明胶海绵和生理盐水对行脊柱内固定术患者术后疼痛的影响。

Medicine:罗哌卡因联合右美托咪定用于骶管麻醉对痔切除术患者的镇痛作用的影响:前瞻性随机对照试验

右美托咪定作为罗哌卡因的辅助用药,延长了骶管阻滞的持续时间,改善了术后镇痛,且其对接受痔切除术的成年患者没有明显的副作用。